-
Innovation Ranking
NewInnovation Ranking – Kyowa Exeo Corp
EXEO Group Inc (EXEO), formerly Kyowa Exeo Corp, is a provider of engineering and system solutions. It designs, constructs, operates, and maintains communication facilities, electrical and air conditioning facilities, new energy-related facilities, urban civil engineering equipment, and water and waste treatment plant equipment. The company offers services covering security, wireless networks, cloud computing, sensors, service-oriented architecture solutions. EXEO constructs telecommunication facilities and provides system solutions for NCCs (new common carriers), cable television companies, government agencies, municipal offices, and railway companies....
-
Innovation Ranking
NewInnovation Ranking – Kyowa Kirin Co Ltd
Kyowa Kirin Co Ltd (Kyowa Kirin), a subsidiary of Kirin Holdings Co Ltd, is a biotechnology company focused on research and development. It is involved in the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, angina pectoris, hypertension,...
-
Product Insights
NewNet Present Value Model: Kyowa Kirin Co Ltd’s Rocatinlimab
Empower your strategies with our Net Present Value Model: Kyowa Kirin Co Ltd's Rocatinlimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Kyowa Kirin Co Ltd’s Bardoxolone Methyl
Empower your strategies with our Net Present Value Model: Kyowa Kirin Co Ltd's Bardoxolone Methyl report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Kyowa Kirin Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Kyowa Kirin Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Sector Analysis
NewCell and Gene Therapies in CNS Disorders – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in CNS Disorders Market Report Overview The cell and gene therapies (CGT) sales in central nervous system (CNS) disorders was $1.5 billion in 2023. It will experience significant growth, achieving a CAGR of more than 42% during the forecast period. Gene therapies will dominate the CGT market in CNS disorders because of strong players such as Sarepta Therapeutics and Novartis with marketed products Elevidys and Zolgensma, respectively. Cell and Gene Therapies in CNS Disorders Market Outlook...
-
Product Insights
NewNet Present Value Model: Ionis Pharmaceuticals Inc’s Evazarsen Sodium
Empower your strategies with our Net Present Value Model: Ionis Pharmaceuticals Inc's Evazarsen Sodium report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rocatinlimab in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rocatinlimab in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rocatinlimab in Atopic Dermatitis (Atopic Eczema) Drug Details: Rocatinlimab is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mogamulizumab in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mogamulizumab in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mogamulizumab in Peripheral T-Cell Lymphomas (PTCL) Drug Details: Mogamulizumab...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Oncolytic Virus To Target CD46 And SLC5A5 For Oncology in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Oncolytic Virus To Target CD46 And SLC5A5 For Oncology in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Oncolytic Virus To...